Keyphrases
Poor Outcome
100%
Diffuse Large B-cell Lymphoma (DLBCL)
100%
Aberrant Methylation
100%
Cell-free DNA (cfDNA)
100%
Death-associated Protein Kinase 1 (DAPK1)
100%
Methylation Status
50%
DBC1
40%
Plasma Samples
40%
Methylation
40%
Delayed Diagnosis
30%
MicroRNA-34a (miR-34a)
20%
Lymphoma Patients
20%
Promoter Methylation
20%
Prognostic Marker
20%
Chemotherapy
10%
Long-term Survivors
10%
Aberrant DNA Methylation
10%
Independent Prognostic Factor
10%
Treatment Response
10%
Multivariate Analysis
10%
Rituximab
10%
Hazard Ratio
10%
Pyrosequencing
10%
Overall Survival Rate
10%
Overall Survival
10%
Treatment Initiation
10%
DNA Methylation (DNAm)
10%
Response to Treatment
10%
5-year Survival
10%
Healthy Individuals
10%
Promoter Region
10%
Prognostic Value
10%
Biochemistry, Genetics and Molecular Biology
B Cell
100%
Methylation
100%
Blood Plasma
100%
DAPK1
83%
DNA Methylation
25%
Promoter Region
16%
Overall Survival
16%
Survival Rate
8%
Rituximab
8%
Pribnow Box
8%
Pyrosequencing
8%
Multivariate Analysis
8%